Co-reporter:Roberto Baccala;Megan J. Welch;Rosana Gonzalez-Quintial;Kevin B. Walsh;John R. Teijaro;Anthony Nguyen;Cherie T. Ng;Brian M. Sullivan;Alessandro Zarpellon;Zaverio M. Ruggeri;Juan Carlos de la Torre;Argyrios N. Theofilopoulos;Michael B. A. Oldstone
PNAS 2014 Volume 111 (Issue 24 ) pp:8925-8930
Publication Date(Web):2014-06-17
DOI:10.1073/pnas.1408148111
The outcome of a viral infection reflects the balance between virus virulence and host susceptibility. The clone 13 (Cl13)
variant of lymphocytic choriomeningitis virus—a prototype of Old World arenaviruses closely related to Lassa fever virus—elicits
in C57BL/6 and BALB/c mice abundant negative immunoregulatory molecules, associated with T-cell exhaustion, negligible T-cell–mediated
injury, and high virus titers that persist. Conversely, here we report that in NZB mice, despite the efficient induction of
immunoregulatory molecules and high viremia, Cl13 generated a robust cytotoxic T-cell response, resulting in thrombocytopenia,
pulmonary endothelial cell loss, vascular leakage, and death within 6–8 d. These pathogenic events required type I IFN (IFN-I)
signaling on nonhematopoietic cells and were completely abrogated by IFN-I receptor blockade. Thus, IFN-I may play a prominent
role in hemorrhagic fevers and other acute virus infections associated with severe vascular pathology, and targeting IFN-I
or downstream effector molecules may be an effective therapeutic approach.
Co-reporter:Amanda L. Blasius;Argyrios N. Theofilopoulos;Keiko Ozato;Dwight H. Kono;Rosana Gonzalez-Quintial;Ivo Rimann;Bruce Beutler
PNAS 2013 Volume 110 (Issue 8 ) pp:2940-2945
Publication Date(Web):2013-02-19
DOI:10.1073/pnas.1222798110
In vitro evidence suggests that plasmacytoid dendritic cells (pDCs) are intimately involved in the pathogenesis of lupus.
However, it remains to be determined whether these cells are required in vivo for disease development, and whether their contribution
is restricted to hyperproduction of type I IFNs. To address these issues, we created lupus-predisposed mice lacking the IFN
regulatory factor 8 (IRF8) or carrying a mutation that impairs the peptide/histidine transporter solute carrier family 15,
member 4 (SLC15A4). IRF8-deficient NZB mice, lacking pDCs, showed almost complete absence of anti-nuclear, anti-chromatin,
and anti-erythrocyte autoantibodies, along with reduced kidney disease. These effects were observed despite normal B-cell
responses to Toll-like receptor (TLR) 7 and TLR9 stimuli and intact humoral responses to conventional T-dependent and -independent
antigens. Moreover, Slc15a4 mutant C57BL/6-Faslpr mice, in which pDCs are present but unable to produce type I IFNs in response to endosomal TLR ligands, also showed an absence
of autoantibodies, reduced lymphadenopathy and splenomegaly, and extended survival. Taken together, our results demonstrate
that pDCs and the production of type I IFNs by these cells are critical contributors to the pathogenesis of lupus-like autoimmunity
in these models. Thus, IRF8 and SLC15A4 may provide important targets for therapeutic intervention in human lupus.